Back to Search Start Over

NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells.

Authors :
Bosch NC
Voll RE
Voskens CJ
Gross S
Seliger B
Schuler G
Schaft N
Dörrie J
Source :
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2019 Dec 11; Vol. 11, pp. 1758835919891622. Date of Electronic Publication: 2019 Dec 11 (Print Publication: 2019).
Publication Year :
2019

Abstract

Background: In therapeutic cancer vaccination, monocyte-derived dendritic cells (moDCs) efficiently activate specific T-cell responses; however, optimizing the activation of innate immune cells could support and improve the antitumor effects. A major disadvantage of moDCs matured with the standard cytokine cocktail (consisting of IL-1β, IL-6, TNFα, and PGE <subscript>2</subscript> ) is their inability to secrete IL-12p70. IL-12 prominently activates natural killer (NK) cells, which are crucial in innate antitumor immunity, as they act as helper cells for the induction of a cytotoxic T lymphocyte (CTL) response and are also able to directly kill the tumor.<br />Methods: Previously we have shown that triggering the NF-κB pathway in moDCs by transfection of mRNA encoding constitutively active IKKβ (caIKKβ) led to IL-12p70 secretion and improved the dendritic cells' capability to activate and expand CTLs with a memory-like phenotype. In this study, we examined whether such dendritic cells could activate autologous NK cells.<br />Results: moDCs matured with the standard cytokine cocktail followed by transfection with the caIKKβ-RNA were able to activate autologous NK cells, detected by the upregulation of CD54, CD69, and CD25 on the NK cells, their ability to secrete IFNγ, and their high lytic activity. Moreover, the ability of NK-cell activation was not diminished by simultaneous T-cell activation.<br />Conclusion: The capacity of caIKKβ-DCs to activate both the adaptive and innate immune response indicates an enhanced potential for clinical efficacy.<br />Competing Interests: Conflict of interest statement: The authors declare the following potential conflict of interest: REV, GS, NS, and JD are named as inventors on a patent on caIKK-RNA-electroporated DCs (WO/2012/055551).<br /> (© The Author(s), 2019.)

Details

Language :
English
ISSN :
1758-8340
Volume :
11
Database :
MEDLINE
Journal :
Therapeutic advances in medical oncology
Publication Type :
Academic Journal
Accession number :
31853267
Full Text :
https://doi.org/10.1177/1758835919891622